I'm speechless.
Firstly because we have an approval.
Secondly because it's deemed to be not price sensitive!
This was supposed to be the saviour of MYX back in 2018-2021 (until Nextstellis came along).
From memory the market size was supposed to over $900M but is now $580M.
MYX have to pay Mithra $6M euro now with another $1.6M euro when it actually launches so I think it's safe to assume that we can write off any profits in the short term. I'm guessing the fact that we're so late to market behind other generic manufacturers means that long term profits are likely to be as abysmal as our other generic products.
The debacle of MYX continues.
Ann: FDA approval of HALOETTE, a generic version of NUVARING, page-2
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$6.10 |
Change
-0.560(8.41%) |
Mkt cap ! $518.9M | |||
| Open | High | Low | Value | Volume |
| $6.62 | $6.62 | $6.10 | $1.789M | 285.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 721 | $6.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.10 | 768 | 1 |
View Market Depth
| Last trade - 16.10pm 15/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$6.14 |
Change
-0.560 ( 7.59 %) |
||||
| Open | High | Low | Volume | ||
| $6.55 | $6.58 | $6.13 | 66128 | ||
| Last updated 15.59pm 15/05/2024 ? | |||||
| MYX (ASX) Chart |